Informa
基調講演
Shalini Andersson, PhD
Developing Next Generation Oligonucleotide Therapeutics
次世代のオリゴヌクレオチド治療薬の開発
AstraZeneca
Sudhir Agrawal
Chemical Engineering of Oligonucleotides: Applications for RNA Therapeutic
オリゴヌクレオチドのケミカルエンジニアリング：RNA治療薬向け用途
Arnay Sciences
Yuji Nishiuchi, Ph.D.
Peptide and Protein Therapeutics Conjugated with Human N-Linked Glycans
ヒトN-結合型グリカンと結合したペプチド・タンパク質治療薬
GlyTech, Inc.
Yutaka Okada
RNAi Therapeutics in Japan: Needs and Solutions-An Alnylam Perspective
日本におけるRNAi治療薬：ニーズと解決策 - Alnylamの見解
Alnylam Japan KK
Leo Qian, PhD
The Endosomal Escape Vehicle Platform of Cyclic Cell-Penetrating Peptides Enhances the Delivery of Oligonucleotides
環状細胞浸透ペプチドのエンドソーム脱出媒体（EEV）プラットフォームによる、オリゴヌクレオチドの送達の改善
Entrada Therapeutics

1日目 -

1日目 -

search
8:00am - 9:00am
登録・コーヒーブレーク
開会前ワークショップ（オプション）
Showing 2 of 2 Streams
9:00am - 9:15am
ワークショップ議長による開会宣言
  • Thomas Rupp - Owner & Principal, Thomas Rupp Consulting, Germany
9:15am - 12:45pm
ワークショップ・アジェンダ

Workshop Description:

This workshop will address different strategies for overcoming manufacturing challenges of synthetic RNA therapeutics. It will also discuss methods for defining CMC control strategies along the development pathway from early clinical development through later stages of development. A variety of different examples and case studies will be presented to give attendees a good understanding of the current bottlenecks, potential solutions and future directions in oligonucleotide CMC and manufacturing.

Who should attend?

Anyone interested in development of oligonucleotide therapeutics; Anyone interested in outsourcing the manufacturing of oligonucleotide therapeutics to a CMO / CRO. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management.








  • Thomas Rupp - Owner & Principal, Thomas Rupp Consulting, Germany
9:00am - 9:15am
ワークショップ議長による開会宣言

Workshop Description:

Peptides fall between small molecules and biologics in terms of molecular weight and size. Additionally, the complexity of peptide therapeutics is increasing with unnatural amino acid substitutions and various covalent modifications (lipidation, PEGylation). This results in analytical challenges! Learn from the experts on strategies and best practices. Hear case studies from companies working in this area.

Who should attend?

Anyone interested in the analysis and bioanalysis of peptide therapeutics. This includes Research scientists, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management

  • Bruce Morimoto, PhD - Vice President, Drug Development, Alto Neuroscience
9:15am - 10:00am
合成ペプチドの精製方法の開発上の課題 - 図解付き事例研究
  • Alaric Desmarchelier, PhD - Business Development Manager - Peptides, Almac Group
10:00am - 10:45am
ペプチド・タンパク質の特性評価手法の最新動向
  • Michael McGinley - Director, Global Applications, Phenomenex
10:45am - 11:15am
ネットワーキング・休憩時間
11:15am - 12:00pm
ペプチドの処方開発における溶解性・物理的安定性の課題
  • Juerg Tschopp, PhD - Principal Scientist, Stratum Medical Corporation
12:00pm - 12:45pm
バイオアナリシス上の課題、ベストプラクティス、事例研究
12:45pm - 1:55pm
ワークショップ閉会、午前中のワークショップ参加者向け昼食会
Showing 1 of 1 Streams
1:55pm - 2:00pm
議長の開会宣言
2:00pm - 2:30pm
次世代のオリゴヌクレオチド治療薬の開発
  • Shalini Andersson, PhD - Vice President of Oligonucleotide Discovery, AstraZeneca
2:30pm - 3:00pm
オリゴヌクレオチドのケミカルエンジニアリング：RNA治療薬向け用途
  • Sudhir Agrawal - President and Founder, Arnay Sciences
3:00pm - 3:30pm
ヒトN-結合型グリカンと結合したペプチド・タンパク質治療薬
  • Yuji Nishiuchi, Ph.D. - Director of Research and Development, GlyTech, Inc.
3:30pm - 4:00pm
ネットワーキング・休憩時間
4:00pm - 4:30pm
日本におけるRNAi治療薬：ニーズと解決策 - Alnylamの見解
  • Yutaka Okada - President and Representative Director, Alnylam Japan KK
4:30pm - 5:00pm
環状細胞浸透ペプチドのエンドソーム脱出媒体（EEV）プラットフォームによる、オリゴヌクレオチドの送達の改善
  • Leo Qian, PhD - Co-Founder and Vice President, Discovery Research, Entrada Therapeutics
5:00pm - 5:30pm
最新の研究成果の発表
5:30pm - 5:35pm
第1日の閉会宣言
Next2日目

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。